



BRITISH GENERIC MANUFACTURERS ASSOCIATION

Friday, January 10th, 2014

Thomas Broeer elected as new BGMA Chair

The British Generic Manufacturers Association (BGMA) has appointed Thomas Broeer, managing director of Kent Pharmaceuticals, as its new chair for the next two years.

He replaces Kim Innes, a director with Teva, who will continue for a further year as vice-chair of the association which is the generic industry's trade body representing more than 90 per cent of the UK supply market.

Thomas brings more than 20 years of international pharmaceutical business management experience to the BGMA role working both within the generic and branded industries. Before taking up the role with Kent Pharmaceuticals earlier this year, Thomas had previously held senior management roles with Mylan in the UK and Germany.

Thomas said: "I am delighted to be taking on the role of chair of the BGMA. Generics play a vital role in the UK in ensuring access to medicines. The competitive, multi-source market delivers huge savings to the NHS every year providing a secure supply of cost effective medicines for patients.

"There are a number of challenges and issues facing the generics industry as business models evolve, regulations change and new opportunities such as biosimilars emerge. The association has a crucial role in all these and I look forward to playing an important part in representing our views."

Thomas added: "I would also like to pay tribute to Kim Innes' contribution over the past two years as Chair of the BGMA. She has been instrumental in driving forward the aims and objectives of the association both within the UK and more widely in Europe."

ENDS

For further information contact:

Jeremy Durrant, 0207 866 7883 / 07792 918648

Jeremy.durrant@britishgenerics.co.uk

Notes for Editors:

Press Release

The British Generic Manufacturers Association represents the interests of UK-based manufacturers and suppliers of generic medicines and promotes the development and understanding of the generic medicines industry in the United Kingdom.

Generic medicines contain the same active ingredient and are as effective as the equivalent brand and cost much less, making the NHS drugs bill affordable. More than two thirds of all medicines dispensed by the NHS are generics yet they cost only around 29% of the NHS drugs bill, a saving of more than £11billion* in England & Wales alone. Without generics, the NHS drugs bill would be approximately twice its current level.

We represent the views and interests of our members and industry to the UK government, the devolved administrations, regulators, other relevant third parties, including where appropriate the Institutions of the European Union.